Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in Interest ReceivablesChange in Net LoansChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

iBio (IBIO) Share-based Compensation (2016 - 2025)

iBio (IBIO) has disclosed Share-based Compensation for 16 consecutive years, with $253000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Share-based Compensation fell 46.74% to $253000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $1.2 million, a 28.85% decrease, with the full-year FY2025 number at $1.5 million, down 24.93% from a year prior.
  • Share-based Compensation was $253000.0 for Q4 2025 at iBio, down from $323000.0 in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $1.6 million in Q1 2023 to a low of $253000.0 in Q4 2025.
  • A 5-year average of $673300.0 and a median of $535500.0 in 2021 define the central range for Share-based Compensation.
  • Peak YoY movement for Share-based Compensation: surged 1471.43% in 2021, then plummeted 71.74% in 2024.
  • iBio's Share-based Compensation stood at $960000.0 in 2021, then fell by 4.69% to $915000.0 in 2022, then plummeted by 50.38% to $454000.0 in 2023, then grew by 4.63% to $475000.0 in 2024, then crashed by 46.74% to $253000.0 in 2025.
  • Per Business Quant, the three most recent readings for IBIO's Share-based Compensation are $253000.0 (Q4 2025), $323000.0 (Q3 2025), and $270000.0 (Q2 2025).